This guideline was provided by the Japanese Association for Complement Research targeting clinicians for making an accurate diagnosis of hereditary angioedema (HAE), and for prompt treatment of the HAE patient in Japan. This is a 2010 year version and will be updated according to any pertinent medical advancements.
dergo unnecessary medical procedures (e.g. appendectomy, exploratory laparotomy). We all hope that patients suffering from the disease will be immediately diagnosed with HAE and treated appropriately. We will update this guideline according to any pertinent medical advancements.
GENERAL INFORMATION ON HAE
a) Epidemiology: one in every 10,000 to 150,000 people (mostly reported as one in every 50,000 
SHORT-TERM PROPHYLAXIS
a) Cases with minimal stress: dental treatment (less invasive), etc. Treatment for prevention is not required, but C1-INH replacement should be ready for use. b) Cases with intensive stress: highly invasive dental treatment, surgical operations, etc. Give C1-INH replacement therapy (for less than 50 kg, 500 units, and for more than 50 kg, 1,000 to 1,500 units, intravenous injection) an hour prior to the operation. Furthermore, a second C1-INH replacement therapy should be prepared.
LONG-TERM PROPHYLAXIS
The following treatment is recommended for patients with a history of laryngeal edema, those who develop symptoms once or more a month, and! or suffered from symptoms for more than 5 days a month. a) Tranexamic acid i) 30-50 mg! kg! day administered in divided doses 2-3 times a day. ii) Adverse reactions: muscle ache, muscle weakness, fatigue, and reduction in blood pressure. b) Danazol i) 2.5 mg! kg! day(maximum 200 mg! day) will be administered for one month, if it is not effective, 300 mg! day will be administered for one month, and if it is still not effective, 400 mg! day will be administered for one month. If 200 mg! day is effective, 100 mg! day will subsequently be administered for one month and the amount will be reduced to 50 mg! day or 100 mg! every second day. ii) Contraindication: children, pregnant women, lactating women, and cancer patients. iii) Adverse reactions: virilization, hepatic disorder, hypertension, lipid abnormality, polycythemia, and hemorrhagic cystitis. iv) Follow-up: Blood testing is required every 6 months. For patients treated with more than 200 mg! day Danazol, an abdominal ultrasonography is required every 6 months and for cases treated with less than 200 mg! day an abdominal ultrasonography is required every year, due to a possibility of hepatic tumorigenesis. Confirm his! her medication history ( especially, antihypertensive drugs, estrogen preparations). In addition, Type 3 has not been reported in Japanese; however, according to reports in Caucasians, it is related to family history and occurs mostly in women.
REFERENCE MATTERS FOR DIAGNOSIS

NOTES
Please contact us if you have any opinions about this guideline. Contact: Takahiko Horiuchi, Steering Committee, The Japanese Association for Complement Research. E-mail: horiuchi@intmed1.med. kyushu-u.ac.jp.
Please refer to our website at http:! ! square.umin.a c.jp! compl!if you have any concerns about C1-INH activity measurement, protein quantitation, and genetic analysis.
C1-INH formulation is provided as Berinert P (trade name)(CSL Behring) in Japan. Information on hereditary angioedema can be obtained from homepage of CSL Behring at http:! ! www.cslbehring.co.jp, or a dedicated website for hereditary angioedema "HAE Information Center" at http:! ! www.hae-info.jp. For example, you can find information like "Tranexamic acid is provided as Transamin (trade name)
